Drugs / MVA-NP+M1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03277456 | Sep → Nov 2017 | — | Barinthus Biotherapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-NP+M1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03277456 ↗ |
| Modality | Vaccine | “MVA-NP+M1, a novel vaccine” NCT03277456 ↗ |
| Route | Intramuscular | “MVA-NP+M1 will be given alone intramuscularly as a single dose.” NCT03277456 ↗ |